Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $17M (up 423.8% year over year) with net income of −$53M.
Q3 2026 key financials · XBRL
- Revenue
- $17M
- +423.8% YoY · +27.2% QoQ
- Net income
- −$53M
- −66.6% YoY · −31.5% QoQ
- Operating margin
- -321.6%
- EPS (diluted)
- −$2.92
- +19.3% YoY · −22.2% QoQ
Source: XBRL data from the Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 10-Q on SEC EDGAR. USD.
Tonix Pharmaceuticals Holding Corp. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $17.2M, up from $3.3M YoY, driven by TONMYA launch
- TONMYA revenue $15.0M, versus Zembrace SymTouch $1.5M and $2.6M YoY
- Operating loss $55.4M vs $33.1M; net loss $53.3M vs $32.0M YoY
- Cash $162.8M; operating cash used $125.6M, financing provided $82.0M through nine months
- Resources expected to last into early third quarter 2027, with additional funding required; going-concern substantial doubt
Risk Factors
- New legal risk: DRL’s October 1, 2026 paragraph IV challenge to four TONMYA patents expiring March 14, 2034
- Patent litigation deadline: 45 days to seek the 30-month FDA approval stay
- Revenue risk: Generic TONMYA could reduce sales volume and pricing after regulatory exclusivity expires in August 2028
- New operational risk: AI inaccuracies could misdirect resources or delay development and regulatory submissions
- New compliance risk: Evolving AI laws may increase compliance costs or limit acceptance of AI-supported analyses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tonix Pharmaceuticals Holding Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.